Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. It has a research collaboration with Keck School of Medicine of University of Southern California using pelareorep in combination with Keytruda, Velcade, and dexamethasone to treat multiple myeloma; and a clinical collaboration with SOLTI breast cancer research. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-403-6707380
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/10/2019 (Estimated)
OptionableNot Optionable
Oncolytics Biotech (TSE:ONC) Frequently Asked Questions
What is Oncolytics Biotech's stock symbol?
Oncolytics Biotech trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ONC."
When is Oncolytics Biotech's next earnings date?
What price target have analysts set for ONC?
1 analysts have issued 12-month target prices for Oncolytics Biotech's stock. Their predictions range from C$10.00 to C$10.00. On average, they anticipate Oncolytics Biotech's stock price to reach C$10.00 in the next twelve months. This suggests a possible upside of 300.0% from the stock's current price. View Analyst Price Targets for Oncolytics Biotech.
What is the consensus analysts' recommendation for Oncolytics Biotech?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oncolytics Biotech.
Has Oncolytics Biotech been receiving favorable news coverage?
News stories about ONC stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Oncolytics Biotech earned a news sentiment score of 0.7 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 7.0 out of 10, meaning that recent press coverage is likely to have an impact on the company's share price in the near future.
Who are some of Oncolytics Biotech's key competitors?
Some companies that are related to Oncolytics Biotech include Cynata Therapeutics (CYP), Arix Bioscience (ARIX), Rafael (RFL), Pfenex (PFNX), Fennec Pharmaceuticals (FRX), BioTime (BTX), Matinas BioPharma (MTNB), Matinas Biopharma (MTNB), Oxford Biodynamics (OBD), Verseon (VSN), Circassia Pharmaceuticals (CIR), Equillium (EQ), Covalon Technologies (COV), Mereo BioPharma Group (MPH) and Neuren Pharmaceuticals (NEU).
What other stocks do shareholders of Oncolytics Biotech own?
Who are Oncolytics Biotech's key executives?
Oncolytics Biotech's management team includes the folowing people:
- Dr. Matthew C. Coffey, Pres, CEO & Director
- Mr. Kirk J. Look, Chief Financial Officer
- Mr. Andrew R. de Guttadauro, Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc (Age 52)
- Mr. Michael Moore, VP of Investor Relations & Corp. Communications
- Dr. Rita Laeufle, Chief Medical Officer
How do I buy shares of Oncolytics Biotech?
Shares of ONC and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Oncolytics Biotech's stock price today?
One share of ONC stock can currently be purchased for approximately C$2.50.
How big of a company is Oncolytics Biotech?
Oncolytics Biotech has a market capitalization of C$47.10 million.
What is Oncolytics Biotech's official website?
How can I contact Oncolytics Biotech?
Oncolytics Biotech's mailing address is 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7, CALGARY, AB 00000, Canada. The company can be reached via phone at +1-403-6707380.
MarketBeat Community Rating for Oncolytics Biotech (TSE ONC)
MarketBeat's community ratings are surveys of what our community members think about Oncolytics Biotech and other stocks. Vote "Outperform" if you believe ONC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONC will underperform the S&P 500 over the long term. You may vote once every thirty days.
